Securities Times News, recently, Minsheng Health (301507.SZ) released the 2023 annual report.The report shows that in 2023, people’s livelihood and health realized operating income of 582 million yuan, an increase of 6.33%year -on -year; net profit attributable to mothers was 85.638 million yuan, an increase of 8.38%year -on -year; net profit after deduction was 79.187 million yuan, an increase of 12.61%year -on -year.At the same time, the company released a full -year profit distribution plan in 2023. It is planned to distribute a cash dividend of 1.00 yuan (tax) per 10 shares. It is expected that the total cash amount will be 35.6554 million yuan (including tax).
It is reported that Minsheng Health focuses on the field of vitamins and mineral supplements. It is a high -tech enterprise that integrates vitamins and minerals and mining materials and health foods.In 1985, it was developed and launched, creating a precedent for the domestic mining industry.
The annual report shows that on the basis of the main brand “21 Jinwei”, people’s livelihood health and actively explore, expand the audience as a “1 belt” manner, expand the industrial boundary, build a brand matrix, and form a brand complementarity.Through the influence of the main brand 21 Jinwei Multidimensional tablets, people’s livelihood health has expanded the non -prescribed drug matrix of calcium tablets, vitamin C, and vitamin E.In addition, Minsheng Health has also created precision vitamin health food matrix with segmented crowds, segmented age, and subdivision functions, such as “21 Jinwei Him+” and the child brand “21 Jinwei Bi Bei+” and the child brand “Xiao Jinwei him “.
In terms of R & D, Minsheng Health has established a multi -departmental cooperation R & D mechanism. Through research and development and innovation, it has vigorously promoted the research and development of new products. In 2023, the investment cost of R & D is 29.5565 million yuan, accounting for 5.08%of the company’s operating income.In multiple sectors such as non -prescription drugs, health foods, probiotics and other sectors, the R & D team has new projects for research. Among them, 3 items of OTC drug registration are completed, 1 drug supplement is completed, 13 new health foods are completed, and newly established functional foods9.
During the reporting period, the company and subsidiaries added 3 new invention patents and 2 utility model patents.As of December 31, 2023, the company and subsidiaries had 61 authorized patents, 9 drug registration approval, and 51 health food approval.
It is worth noting that the company’s probiotic sector gradually expands the Rongsheng bacteria strain library on the basis of the original professional probiotic brand “Puriest”, and completes some of its own strain identification and preservation work.The MSJK0025 strain completed the research of intestinal implants internal test and improved the experimental research of mastitis body, the tons of process optimization and testing; the MSJK0068 strain completed the test research of cholesterol body, starting the tonnage process optimization and testing;Blood lipidal test research.
Minsheng Health said that in the future, the company will always focus on the field of vitamins and mineral supplements necessary for the human body. Guiders are guided by innovating the concepts of innovation and healthy development.And market leading life and health enterprises.(Li Ping)
